Provided herein are liposomal compositions for improved delivery and penetration into the skin. Liposomal compositions as provided herein comprise one more peptides. Also provided herein are compositions and methods for targeting dermal white adipose tissue to improve fat reduction and anti-aging effects. Compositions and methods for targeting dermal white adipose tissue may comprise administering a composition comprising liposomes.

A liposome for delivery of nucleic acid is provided herein, comprising cationic lipid compound, a phospholipid and a PEGylated lipid, wherein the cationic lipid compound is in an amount from 50 wt % to 90 wt % and consist of a lipid compound and a cholesterol lipid compound. A nucleic acid liposome formulation comprising the said liposome and the nucleic acid encapsulated by the liposome and the method for preparing the same are provided therein. Increased amount of nucleic acid can be loaded into the nucleic acid liposome formulation as described therein. Thus, at the same dosage, intake of the cationic lipid compound is decreased, thereby decreasing toxicity.

Disclosed herein are method and compositions for making and using liposomes having small diameters and low polydispersity.

The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL). In the preferred embodiment the drug in the solubilizing agent is mixed with the liposomes in aqueous suspension so that the concentration of solubilizing agent is lowered to below its capacity to completely solubilize the drug. This results in the drug precipitating but remote loading capability is retained. The process is scalable and, in liposomes in which the lipid composition and remote loading agent are optimized, the resulting drug-loaded liposomes are characterized by a high drug-to-lipid ratios and prolonged drug retention when the liposome encapsulated drug is administered to a subject.

Provided herein are pharmaceutical compositions containing (a) at least one liposome includes at least one vesicle-forming phospholipid; and (b) treprostinil encapsulated within the liposome. The ratio of treprostinil to phospholipid is equal to or higher than 0.035 and provides a controlled release of treprostinil. Also provided is the use of the pharmaceutical compositions to treat respiratory diseases.

Provided herein are hypoxia/acidic targeting compounds formulated in lipid-containing nanoparticles (liposomes) containing a diagnostic and/or a therapeutic agent. These nanoparticles can penetrate the blood-brain barrier (BBB) and are useful in the treatment ischemic conditions, as well as systemic conditions with hypoxic environments, such as tumors.

Liposomes with an entrapped amphipathic weak base and alkyl or aryl sulfonate are described as well as methods of making and using these liposomes.

Echogenic liposomes (ELIP) formulated with an at least partially pegylated phospholipid bi-layer shell, encapsulated nitric oxide, and encapsulated perfluorocarbon of the formula CxFy in a ratio of about 1:1 by volume, wherein X is greater than or equal to 3, are disclosed, along with methods for treating a patients suffering from cardiovascular disease by administering the ELIP at a site remote from the target diseased section, monitoring presence of the ELIP at the target diseased section, and administering ultrasound upon detection of presence such that bioactive NO is released at the target diseased section.

Hyperstable liposome comprising an anti-mitotic agent, one or more anions and one or more cations entrapped in the inner milieu, wherein the entrapped anti-mitotic drug is released at a slow rate that is less than 0.6% in 12 hours or less than 5% in 8 hours when the liposomes are suspended in 600 mM sucrose. These liposomes are useful in the treatment of cancer. In particular, HEPC:Chol:DSPE-PEG2000 (50:45:5) liposomes comprising BI 2536 and citrate:phosphate in a ratio of 1:3.

The present invention provides a preparation method of a redox-responsive chitosan-liposome and use thereof, wherein the method uses dithiobis succinimidyl-substituted ester to synthesize a redox-responsive and disulphide bonded double fatty chain substituent phosphatidylethanolamine-s-s-chitosan. Using the synthesized double fatty chain substituent phosphatidylethanolamine chitosan, by a post-insertion and self-assembly method, to modify liposome, to construct a double fatty chain substituent phosphatidylethanolamine chitosan-liposome drug carrier having a redox-responsive chitosan brush on the surface thereof. The chitosan-liposome constructed in the present invention not only has the strong cell adhesion property and the antiserum property, but also has environmental response properties, being suitable for the intravenous injection. The present invention also provides the use of the chitosan-liposome encapsulating super-paramagnetic ferroferric oxide nanoparticles in drug delivery, which has high drug delivery efficiency and high biocompatibility, and has broad application prospects.